These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19456876)

  • 1. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
    Bonnet PO; Yoon BS; Wong WY; Boswell K; Ewenstein BM
    Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U; Livnat T; Zivelin A; Kenet G
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
    Steen Carlsson K; Astermark J; Donfield S; Berntorp E
    Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
    Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
    Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Knight C; Danø AM; Kennedy-Martin T
    Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
    Holme PA; Glomstein A; Grønhaug S; Tjønnfjord GE
    Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.
    Putnam KG; Bohn RL; Ewenstein BM; Winkelmayer WC; Avorn J
    Haemophilia; 2005 May; 11(3):261-9. PubMed ID: 15876272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW; Lee SY; Park SK
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
    Hay JW; Zhou ZY
    Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience.
    Rodriguez-Merchan EC; Jimenez-Yuste V; Gomez-Cardero P; Alvarez-Roman M; Martin-Salces M; Rodriguez de la Rua A
    Haemophilia; 2010 May; 16(102):84-8. PubMed ID: 20536990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
    Szmurło D; Deryło Ł; Ryś P; Władysiuk M
    Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
    Hay JW; Chaugule SC; Young G
    Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
    Economou M; Teli A; Tzantzaroudi A; Tsatra I; Zavitsanakis A; Athanassiou-Metaxa M
    Haemophilia; 2008 Mar; 14(2):390-1. PubMed ID: 18194305
    [No Abstract]   [Full Text] [Related]  

  • 18. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.
    Hay JW; Zhou ZY
    J Med Econ; 2011; 14(4):516-25. PubMed ID: 21699366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
    Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
    Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.
    Mareque M; Mingot-Castellano ME; López-Fernández MF; Álvarez-Román MT; Oyagüez I
    Eur J Haematol; 2020 Jul; 105(1):94-100. PubMed ID: 32220097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.